Details for Patent: 6,605,644

Title:	Analgesic regimen
Abstract:	A regimen for the administration of tramadol for the treatment of analgesia is described. The regimen involves a slower initial titration rate of tramadol which results in a significantly lower percentage of discontinuations of therapy due to a lower incidence and severity of side effects.
Inventor(s):	Kamin; Marc (West Windsor, NJ), Olson; William (Princeton, NJ)
Assignee:	Ortho-McNeil Pharmaceutical, Inc. (Raritan, NJ)
Filing Date:	Oct 26, 2001
Application Number:	10/002,249
Claims:	1. A regimen for the treatment of pain which comprises administering to one in need thereof about 25 mg tramadol on days 1-3; about 50 mg of tramadol on days 4-6; about 75 mg of tramadol on days 7-9; about 100 mg of tramadol on days 10-12; about 150 mg of tramadol on days .+-.3-15; about 200 mg of tramadol on days 16-18 and about 200 mg to about 400 mg of tramadol per day thereafter, in the form of a pharmaceutical composition containing tramadol as the active ingredient; whereby discontinuations due to adverse side effects are reduced. 2. A regimen for the treatment of pain which comprises administering to one in need thereof about 25 mg tramadol on days 1-3; about 50 mg of tramadol on days 4-6; about 75 mg of tramadol on days 7-9; about 100 mg of tramadol on days 10-12; about 150 mg of tramadol on days .+-.3-15; and about 200 mg on day 16, in the form of a pharmaceutical composition containing tramadol as the active ingredient; whereby discontinuations due to adverse side effects are reduced. 3. A regimen for the treatment of pain which comprises administering to one in need thereof about 25 mg of tramadol on days 1-3; about 50 mg of tramadol on days 4-6; about 75 mg of tramadol on days 7-9; about 100 mg of tramadol on days 10-12; about 150 mg of tramadol on days 13-15; and about 200 mg on days 16-18, in the form of a pharmaceutical composition containing tramadol as the active ingredient; whereby discontinuations due to adverse side effects are reduced. 4. A regimen for the treatment of pain which comprises administering to one in need thereof about 25 mg tramadol on days 1-3; about 50 mg of tramadol on days 4-6; about 75 mg of tramadol on days 7-9; about 100 mg of tramadol on days 10-12, in the form of a pharmaceutical composition containing tramadol as the active ingredient; whereby discontinuations due to adverse side effects are reduced. 5. The regimen the treatment of pain according to claim 2 which comprises administering to for in need thereof about 25 mg of tramadol q.d. on days 1-3, about 25 of mg of tramadol b.i.d. on days 4-6, about 25 mg of tramadol t.i.d. on days 7-9, about 25 mg of tramadol q.i.d. on days 10-12, and about 50 mg of tramadol t.i.d. on days 13-15, and about 50 mg of tramadol q.i.d. on day 16, in the form of a pharmaceutical composition containing tramadol as the active ingredient; whereby discontinuations due to adverse side effects are reduced. 6. The regimen for the treatment of pain according to claim 2 which comprises administering to one in need thereof about 25 mg of tramadol q.d. on days 1-3, about 25 of mg of tramadol b.i.d. on days 4-6, about 25 mg of tramadol t.i.d. on days 79, about 25 mg of tramadol q.i.d. on days 10-12, and about 50 mg of tramadol t.i.d. on days 13-15, and about 50 mg of tramadol q.i.d. on days 16-18, in the form of a pharmaceutical composition containing tramadol as the active ingredient; whereby discontinuations due to adverse side effects are reduced. 7. The regimen for the treatment of pain according to claim 1, which comprises administering to one in need thereof about 25 mg of tramadol q.d. on days 1-3, about 25 of mg of tramadol b.i.d. on days 4-6, about 25 mg of tramadol t.i.d. on days 7-9, about 25 mg of tramadol q.i.d. on days 10-12, and about 50 mg of tramadol t.i.d. on days 13-15, about 50 mg of tramadol q.i.d. on days 16-18 and about 50-100 mg of tramadol q.i.d. thereafter, in the form of a pharmaceutical composition containing tramadol as the active ingredient; whereby discontinuations due to adverse side effects are reduced. 8. The regimen for the treatment of pain according to claim 4, which comprises administering to on in need thereof about 25 mg of tramadol q.d. on days 1-3, about 25 of mg of tramadol b.i.d. on days 4-6, about 25 mg of tramadol t.i.d. on days 7-9, about 25 mg of tramadol q.i.d. on days 10-12, in the form of a pharmaceutical composition containing tramadol as the active ingredient; whereby discontinuations due to adverse side effects are reduced. 9. A regimen for the treatment of pain which comprises administering to one in need thereof about 25 mg tramadol on days 1-3; about 50 mg of tramadol on days 4-6; about 75 mg of tramadol on days 7-9; about 100 mg of tramadol on days 10-12; about 150 mg of tramadol on days 13-15, in the form of a pharmaceutical composition containing tramadol as the active ingredient; whereby discontinuations due to adverse side effects are reduced. 10. A regimen for the treatment of pain which comprises administering to one in need thereof about 25 mg tramadol on days 1-3; about 50 mg of tramadol on days 4-6; about 75 mg of tramadol on days 7-9; about 100 mg of tramadol on days 10-12; about 150 mg of tramadol on days 13-15, and thereafter, in the form of a pharmaceutical composition containing tramadol as the active ingredient; whereby discontinuations due to adverse side effects are reduced. 11. The regimen or the treatment of pain according to claim 10, which comprises administering to one in need thereof about 25 mg of tramadol q.d. on days 1-3, about 25 of mg of tramadol t.i.d. on days 4-6, about 25 mg of tramadol t.i.d. on days 7-9, about 25 mg of tramadol q.i.d. on days 10-12, and about 50 mg of tramadol t.i.d. on days 13-15 and thereafter, in the form of a pharmaceutical composition containing tramadol as the active ingredient; whereby discontinuations due to adverse side effects are reduced.